The goal of this clinical trial is to learn about TLPO cancer vaccine in cases of solid tumor malignancies. The main objectives it aims to learn about are:
* What is the time to progression/recurrence of disease after vaccination with the autologous TLPO vaccine in multiple solid tumor malignancies?
* What is the overall survival after vaccination with the autologous TLPO vaccine in multiple solid tumor malignancies?
* What are the safety characteristics of autologous TLPO using standardized criteria (Common Terminology Criteria for Adverse Events v5.0)
* Does TPLO generate an immune response?
* Determine the presence, rate, and duration of any disease control response affected by TPLO.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patient must be ≥18 years of age.
✓. Stage I-IV patients.
✓. Demonstrated tolerance of maintenance or adjuvant immunotherapy, targeted therapy, and/or hormonal therapy for three doses (if maintenance therapy is indicated)
✓. ECOG 0-1 performance.
✓. Patient must have a predicted life expectancy of ≥ 6 months.
✓. No uncontrolled or life-threatening health conditions.
✓. No active, acute infections
✓. Patient must have the following laboratory values (obtained ≤28 days prior to enrollment):
Exclusion criteria
✕. Steroids, immunosuppressive therapy (to include mTOR inhibitors), or cytotoxic chemotherapy within 30 days of enrollment.
✕. Untreated or progressing brain metastases. Treated stable brain metastases that have not progressed for at least 3 months will be permitted at the PI's discretion.
✕. Rapidly progressive disease or visceral crisis
✕. Patient has undergone or is anticipated to undergo organ transplantation including allogeneic or autologous stem-cell transplantation, at any time
✕. Patient has a diagnosis of immunodeficiency, either primary or acquired.